FindTrial
Sign In

This study is to treat the melasma (black spots on face by giving intralesional tranexamic acid for treatment of melasma in male patients

To study the efficacy and safety of intralesional tranexamic acid for treatment of melasma in male patients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/07/020190
Enrollment
50
Registered
2019-07-15
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L814- Other melanin hyperpigmentation

Interventions

Intervention1: Intralesional tranenexamic acid 25mg/ml will be given to all the randomised patients on the lesions of melasma on the interval of 4week total 4 dosage...: Outcome to be assessed at 6wee

Sponsors

Himachal Pradesh university
Lead Sponsor
Dr RPGMC TANDA
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: Healthy volunteer

Exclusion criteria

Exclusion criteria: 1 patient with realistic expectations 2 female, 3 bleeding disorders, 4 using any other treatment modalities for melasma in previous 6 months

Design outcomes

Primary

MeasureTime frame
Total reduction in Melasma area severity index,at 4,8,12,16 weekTimepoint: 16 weeks—

Secondary

MeasureTime frame
MASI score at 16 weeksTimepoint: At 4weeks interval for 4 times total for sixteen Weeks—

Countries

India

Contacts

Public ContactYog Raj

Dr RPGMC TANDA KANGRA

vkm1@rediffmail.com9816930531

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026